STOCK TITAN

EyePoint (EYPT) CEO Duker reports RSU vesting and tax-share withholding

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

EyePoint, Inc. President and CEO Jay S. Duker, who also serves as a director, reported routine equity activity on January 6, 2026 related to previously granted restricted stock units. A block of 20,793 restricted stock units converted into the same number of shares of common stock at an exercise price of $0.00, reflecting vesting of his equity award. To cover taxes on this vesting, 10,054 shares of common stock were withheld by EyePoint at a price of $16.86, and the filing specifies that no shares were sold in the market. After these transactions, Duker directly held 77,752 shares of common stock, and an additional 99,165 shares were reported as indirectly held by a family trust for the benefit of his children, for which he disclaims beneficial ownership.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Duker Jay S.

(Last) (First) (Middle)
C/O EYEPOINT, INC.
480 PLEASANT STREET, SUITE C400

(Street)
WATERTOWN MA 02472

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EyePoint, Inc. [ EYPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 M 20,793 A $0.00 87,806 D
Common Stock 01/06/2026 F 10,054 D $16.86(1) 77,752 D
Common Stock 99,165 I By Family Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0.00 01/06/2026 M 20,793 (3) (3) Common Stock 20,793 $0.00 0.00 D
Explanation of Responses:
1. No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
2. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
3. The restricted stock units vest in three ratable annual installments beginning January 6, 2024.
Remarks:
/s/ Ron Honig, Attorney-in-Fact 01/07/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EyePoint (EYPT) report for CEO Jay S. Duker?

Jay S. Duker reported the vesting and conversion of 20,793 restricted stock units into the same number of EyePoint common shares on January 6, 2026, at an exercise price of $0.00.

Were any EyePoint (EYPT) shares sold by the CEO in this Form 4 filing?

No market sale occurred. The filing explains that 10,054 shares were withheld by EyePoint to satisfy tax withholding obligations related to the RSU vesting, and explicitly notes that no shares were sold.

How many EyePoint (EYPT) shares does the CEO directly own after the reported transactions?

Following the January 6, 2026 transactions, Jay S. Duker directly owned 77,752 shares of EyePoint common stock.

What EyePoint (EYPT) shares are held through the family trust mentioned in the Form 4?

The filing reports 99,165 shares of EyePoint common stock as indirectly held by a Family Trust for the benefit of the CEO’s children, and states that he disclaims beneficial ownership of these securities.

At what price were EyePoint (EYPT) shares withheld for taxes in this Form 4?

The 10,054 shares withheld to cover tax obligations related to the RSU vesting were valued at $16.86 per share, according to the filing.

How do the restricted stock units for the EyePoint (EYPT) CEO vest over time?

The filing notes that the restricted stock units vest in three ratable annual installments beginning on January 6, 2024, leading to the January 6, 2026 vesting event.

EyePoint

NASDAQ:EYPT

EYPT Rankings

EYPT Latest News

EYPT Latest SEC Filings

EYPT Stock Data

1.05B
77.53M
3.51%
101.33%
12.26%
Biotechnology
Laboratory Analytical Instruments
Link
United States
WATERTOWN